| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 12/27/2002 | WO2001087935A9 Methods of modulating angiogenesis by regulating the expression of pituitary tumor transforming gene (pttg) |
| 12/27/2002 | WO2001078706A9 Treatment of hyperproliferative, inflammatory and related mucocutaneous disorders using inhibitors of mevalonate synthesis and metabolism |
| 12/27/2002 | WO2001052904A9 Pharmaceutical compositions and methods of treatment based on vegf antisense oligonucleotides |
| 12/27/2002 | WO2001052855A8 Drug combination for the treatment of depression and related disorders comprising mirtazapine and gepirone |
| 12/27/2002 | WO2001034631A3 PEPTIDE ANALOGS AND MIMETICS SUITABLE FOR IN VIVO USE IN THE TREATMENT OF DISEASES ASSOCIATED WITH ABNORMAL PROTEIN FOLDING INTO AMYLOID, AMYLOID-LIKE DEPOSITS OR β-SHEET RICH PATHOLOGICAL PRECURSOR THEREOF |
| 12/27/2002 | WO2001030336A9 Pharmaceutical formulations comprising resveratrol and use thereof |
| 12/27/2002 | WO2001021574A9 Systems and methods for opening obstructed biological conduits |
| 12/27/2002 | CA2782868A1 Polymorphic forms of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoylbenzofuran-5-yl)piperazine hydrochloride |
| 12/27/2002 | CA2782865A1 Polymorphic forms of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoylbenzofuran-5-yl)piperazine hydrochloride |
| 12/27/2002 | CA2782862A1 Polymorphic forms of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoylbenzofuran-5-yl)piperazine hydrochloride |
| 12/27/2002 | CA2782857A1 Polymorphic forms of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoylbenzofuran-5-yl)piperazine hydrochloride |
| 12/27/2002 | CA2782791A1 Polymorphic forms of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoylbenzofuran-5-yl)piperazine hydrochloride |
| 12/27/2002 | CA2782761A1 Polymorphic forms of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoylbenzofuran-5-yl)piperazine hydrochloride |
| 12/27/2002 | CA2782628A1 Polymorphic forms of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoylbenzofuran-5-yl)piperazine hydrochloride |
| 12/27/2002 | CA2782623A1 Polymorphic forms of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoylbenzofuran-5-yl)piperazine hydrochloride |
| 12/27/2002 | CA2782615A1 Polymorphic forms of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoylbenzofuran-5-yl)piperazine hydrochloride |
| 12/27/2002 | CA2782521A1 Polymorphic forms of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoylbenzofuran-5-yl) piperazine hydrochloride |
| 12/27/2002 | CA2782519A1 Polymorphic forms of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoylbenzofuran-5-yl) piperazine hydrochloride |
| 12/27/2002 | CA2782517A1 Polymorphic forms of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoylbenzofuran-5-yl) piperazine hydrochloride |
| 12/27/2002 | CA2782515A1 Polymorphic forms of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoylbenzofuran-5-yl)piperazine hydrochloride |
| 12/27/2002 | CA2782494A1 Polymorphic forms of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoylbenzofuran-5-yl)piperazine hydrochloride |
| 12/27/2002 | CA2753372A1 Mutations in the bcr-abl tyrosine kinase associated with resistance to sti-571 |
| 12/27/2002 | CA2646802A1 Novel crystalline forms of 4-[4-[4-(hydroxydiphenylmethyl)-1-piperidinyl]-1-hydroxybutyl]-.alpha.,.alpha.-dimethylbenzene acetic acid and its hydrochloride |
| 12/27/2002 | CA2456685A1 Antibacterial treatment of osteoarthritis |
| 12/27/2002 | CA2451874A1 Antisense oligonucleotides which can inhibit the formation of capillary tubes by endothelial cells |
| 12/27/2002 | CA2451638A1 Deuterated n-substituted and .alpha.-substituted diphenylalkoxy acetic acid amino alkyl esters and medicaments containing these compounds |
| 12/27/2002 | CA2451475A1 Agent for protection of retinal neurons |
| 12/27/2002 | CA2450936A1 Purine inhibitors of phosphodiesterase (pde) 7 |
| 12/27/2002 | CA2450934A1 Pyrimidine inhibitors of phosphodiesterase (pde) 7 |
| 12/27/2002 | CA2450856A1 Novel aliphatic compounds, their synthesis method, and utilization method of the same |
| 12/27/2002 | CA2450724A1 Quinazoline and pyrido¬2,3-d|pyrimidine inhibitors of phosphodiesterase (pde) 7 |
| 12/27/2002 | CA2450666A1 Diagnosing tumorigenicity and determining resistance to anticancer therapy |
| 12/27/2002 | CA2450659A1 Tryptase inhibitors |
| 12/27/2002 | CA2450590A1 Methods and compositions for inhibiting, preventing or reducing tumor cell growth in patients resistant to the antineoplastic effects of antiestrogen therapy |
| 12/27/2002 | CA2450245A1 4-piperazinylindole derivatives with 5-ht6 receptor affinity |
| 12/27/2002 | CA2450159A1 Methods for modulating gap junctions |
| 12/27/2002 | CA2450074A1 Acylic piperazine and piperidine derivatives which are useful for treating neuronal damage |
| 12/27/2002 | CA2449977A1 Human growth hormone antagonists |
| 12/27/2002 | CA2449950A1 Agents for treating diseases caused by nonsense mutation |
| 12/27/2002 | CA2449916A1 Imidazole derivatives for modulating sodium channels |
| 12/27/2002 | CA2449898A1 Krill and/or marine extracts for prevention and/or treatment of cardiovascular diseases, arthritis, skin cancer, diabetes, premenstrual syndrome and transdermal transport |
| 12/27/2002 | CA2449754A1 Immune response modifiers for the treatment of periodontal disease |
| 12/27/2002 | CA2449212A1 Alkylidene pyrazolidinedione derivatives and use for treating diabetes and obesity |
| 12/27/2002 | CA2448993A1 Process for the preparation of dispersions |
| 12/27/2002 | CA2448526A1 N-formyl hydroxylamine compounds as inhibitors of pdf |
| 12/27/2002 | CA2448298A1 Phenylpyridine carbonyl piperazine derivative |
| 12/27/2002 | CA2447808A1 A process for preparing paroxetine hci which limits formation of pink colored compounds |
| 12/27/2002 | CA2447624A1 Anti-tumour compound |
| 12/27/2002 | CA2446963A1 Quinazolinediones as antibacterial agents |
| 12/27/2002 | CA2446931A1 Pyrrolidine bicyclic compounds |
| 12/27/2002 | CA2445731A1 Method and nucleic acids for the differentiation of prostate tumors |
| 12/27/2002 | CA2444876A1 Treatment of dementia and neurodegenerative diseases with intermediate doses of lhrh antagonists |
| 12/27/2002 | CA2444356A1 Orally deliverable pharmaceutical composition comprising an active compound having an aminosulfonyl group (cox-2 inhibitor), a polyethylene glycol and a free-radical scavenging antioxidant |
| 12/27/2002 | CA2443466A1 An aqueous pharmaceutical preparation of cilostazol for parenteral use |
| 12/27/2002 | CA2429113A1 Monocyclic or bicyclic carbocycles and heterocycles as factor xa inhibitors |
| 12/27/2002 | CA2422745A1 Novel bicyclic isoxazolinones as antibacterial agents |
| 12/27/2002 | CA2418102A1 Combretastatin a-3 prodrug |
| 12/26/2002 | US20020198571 Methods of indirectly stimulating the vagus nerve with an electrical field |
| 12/26/2002 | US20020198570 Apparatus for indirectly stimulating the vagus nerve with an electrical field |
| 12/26/2002 | US20020198567 Electro-endocytotic therapy as a treatment modality of cancer |
| 12/26/2002 | US20020198415 Producing vegetation water from olives; adding acid; incubating the acidified vegetation water for a period of at least two months, until at least 75% of oleoeuropein has been converted to hydroxytyrosol |
| 12/26/2002 | US20020198407 Antiallergy agents and bronchodilators |
| 12/26/2002 | US20020198396 Oxime-group containing oestrone sulphatase inhibitors |
| 12/26/2002 | US20020198387 Reacting N-alkylpiperidine with a haloformic acid ester to prepare an alkoxycarbonylpiperidine, hydrolyzing |
| 12/26/2002 | US20020198382 For therapy and prophylaxis disorders caused by disturbances of glucose and/or lipid metabolism, such as, for example diabetes type 2, and other insulin-resistant conditions |
| 12/26/2002 | US20020198379 Active compound from a sponge |
| 12/26/2002 | US20020198377 For improving perception, concentration power, learning power and/ or memory power |
| 12/26/2002 | US20020198374 Steroids substituted at the 11 - position, process for their preparation, their use as medicament and the pharmaceutical compositions containing them |
| 12/26/2002 | US20020198372 Methods for purifying nucleic acids |
| 12/26/2002 | US20020198367 DNA encoding mammalian neuropeptide FF (NPFF) receptors and uses thereof |
| 12/26/2002 | US20020198266 Skin remedy, which allows gas transportation therethrough |
| 12/26/2002 | US20020198265 Antiseptic spermicidal composition and means for its application |
| 12/26/2002 | US20020198264 Potentiating toxicity of 1,3-bis(chloroethyl)2-nitrosourea |
| 12/26/2002 | US20020198263 Preventing or treating deficiency by administering l-carnitine or a salt |
| 12/26/2002 | US20020198262 Alanine-and glycine-containing therapeutic agent for hepatitis |
| 12/26/2002 | US20020198261 Liquid pharmaceutical compositions |
| 12/26/2002 | US20020198260 Polyoxyethylene glycol lipid compounds with long chain fatty acid pendant groups |
| 12/26/2002 | US20020198259 Treatment of disease caused by procedural vascular trauma and/or an increased level of plasma homocysteine |
| 12/26/2002 | US20020198258 Therapeutic substances and methods of making and using same |
| 12/26/2002 | US20020198257 Halogenated 2-phenyl-1,2-ethanediol monocarbamate derivatives |
| 12/26/2002 | US20020198256 Laulimalide microtubule stabilizing agents |
| 12/26/2002 | US20020198255 2,4-substituted pyrrolidine derivatives-CCR-3 receptor antagonists |
| 12/26/2002 | US20020198253 Melatonin derivatives and medicine containing same |
| 12/26/2002 | US20020198251 Substituted 2-dialkylaminoalkylbiphenyl derivatives |
| 12/26/2002 | US20020198250 Pyrrolidine derivative hair growth compositions and uses |
| 12/26/2002 | US20020198249 Cyclopentane heptan(ENE)oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents |
| 12/26/2002 | US20020198248 Therapeutic methods and compositions involving isoflavones |
| 12/26/2002 | US20020198247 Pharmaceutical composition for inhibiting the growth of viruses and cancers |
| 12/26/2002 | US20020198246 Agent for preventing and/or treating sinusitis |
| 12/26/2002 | US20020198245 Heterocyclic aromatic oxazole compounds and use thereof |
| 12/26/2002 | US20020198244 Heterocyclic aromatic oxazole compounds and use thereof |
| 12/26/2002 | US20020198243 Cyclizing the tert-butyl-thiourea derivative to form the end product |
| 12/26/2002 | US20020198242 Administering to an animal an effective dose of atleast an enzyme Dipeptidyl Peptidase (DP IV) enzyme activity effector to increase the capacity of insulin producing cells |
| 12/26/2002 | US20020198241 Inhibiting bacterial growth in humans and nonhuman mammals by administering to the patient an antibacterially effective dose of hydroxamic acid derivatives containing carbamoyl groups |
| 12/26/2002 | US20020198239 Oxidizing 5-methoxy-2-(((4-methoxy-3,5-dimethyl-2-pyridinyl)-methyl)thio)-1H -benzimidazole into S-omeprazole in an organic solvent, convering formed S-omeprazole into corresponding potassium salt by treating with potassium source |
| 12/26/2002 | US20020198238 Bipyridyl compounds with specific physical properties are potent and selective cyclooxygenase-2 (COX-2) inhibitor |
| 12/26/2002 | US20020198237 2,5-substituted imidazole compounds useful as histamine H3 receptor mediators |
| 12/26/2002 | US20020198236 Small organic molecule regulators of cell proliferation |
| 12/26/2002 | US20020198235 Use of benzothiopenes to treat and prevent prostate cancer |
| 12/26/2002 | US20020198234 Identifying a patient suffering from fatigue arising from oncological condition, and administering to the patient a therapeutically effective amount of D-threo-methylphenidate free of 1-threo isomer |